MRI for Prostate Cancer Staging

Digital rectal exams for prostate cancer staging could become a thing of the past thanks to MRI. A new study in JAMA Network Open found that MRI performed as well as digital exams in determining the extent of prostate cancer disease.

Prostate cancer screening is moving closer to becoming a more widely accepted test, and MRI has played a major role in that evolution by enabling more precise workup of men with high PSA levels.

  • But what about other aspects of prostate cancer diagnosis and treatment, such as staging men found to have clinically significant disease? It turns out MRI has a role to play there as well. 

To learn more, researchers from Germany looked at data from 4.4k men with a median age of 66 and median PSA level of 7.4 ng/mL (anything over 3 ng/mL is typically referred for additional workup). All patients were scheduled for radical prostatectomy. 

  • Patients received digital rectal exams to assign clinical T stage and assess characteristics of cancer severity, such as local tumor extent, extracapsular extension, and seminal vesicle invasion. 

This was compared to multiparametric MRI scans on 1.5T or 3T systems, with data reported using the PI-RADS scale. The study’s primary outcome was distant metastasis-free survival. 

Among the patient cohort, researchers found…

  • MRI staging was slightly more accurate than digital exams for predicting biochemical recurrence-free survival (C index = 0.62, with 0.5 representing chance-level prediction and 1 indicating perfect prediction). 
  • And MRI was also better at predicting distant metastasis-free survival (C index = 0.67).
  • But MRI and digital exams were comparable when using four of the major prostate cancer risk classification systems in Europe.

What to make of the results? MRI didn’t have a huge advantage over digital rectal exams, but it was good enough for the authors to suggest that digital exams could be eliminated in favor of MRI workup instead.

  • That would enable clinicians to avoid many of the digital exam’s shortcomings, such as subjectivity, operator dependency, and restricted ability to assess extracapsular extension or seminal vesicle invasion.

The Takeaway

This week’s study shows that MRI’s role in prostate cancer diagnosis and treatment goes beyond just screening, and the digital rectal exam’s role for patient staging could soon become a thing of the past in all but a few cases. 

A Case for Multiparametric Ultrasound

A new Lancet study out of the UK provided the strongest evidence yet that multiparametric ultrasound might deserve a core role in prostate cancer screening, either as a complement or alternative to multiparametric MRI. That could be a big deal given mpMRI’s cost, time, and accessibility challenges, and makes this study worth a deeper look.

The Study – The researchers performed mpUS and mpMRI exams on 306 patients with signs of prostate cancer (either elevated PSAs or abnormal rectal exams), and then conducted targeted biopsies on the 257 patients who had positive imaging findings. 

The biopsy results revealed cancer in 133 patients, including 83 clinically significant cancers, while showing how mpUS might contribute to prostate cancer diagnosis:

  • mpUS was positive in 272 patients (89%)
  • mpMRI was positive in 238 patients (78%)
  • mpUS identified 66 clinically significant cases (79%)
  • mPMRI identified 77 clinically significant cases (93%)
  • mpMRI and mpUS combined to detect all 83 clinically significant cancers
  • mpUS exclusively detected 6 clinically significant cancers 
  • mpMRI exclusively detected 17 clinically significant cancers

In other words, mpUS was only slightly less accurate than mpMRI for clinically significant cancer detection (-4.3%), but led to far more biopsies (+11.1%), while the combined modalities notably improved clinically significant cancer detection (+7.2%). 

The Takeaway

mpMRI’s role in prostate cancer screening is still secure, but this study shows that mpUS could improve cancer detection if the modalities are used together. Perhaps more importantly, it suggests that mpUS could be a valid prostate cancer detection option for the half of the world that doesn’t have access to advanced imaging or for the many patients who can’t/won’t undergo MRI (orthopedic implants, claustrophobia etc.).

The PSMA PET/CT + mpMRI PCa Effect

There’s been a growing number of studies comparing 68Ga-PSMA PET/CT and mpMRI’s effectiveness along the prostate cancer pathway, but new research suggests that the modalities might be particularly effective if used together early in the diagnostic process.

The Study – A team of Australian researchers reviewed pre-operative mpMRI and 68Ga-PSMA PET/CT exams from 1,123 men (median PSA = 6), comparing their imaging results and histology findings. Here’s what they discovered:

  • mpMRI identified tumors in 93 men (8%) that were missed by 68Ga-PSMA PET/CT
  • 68Ga-PSMA PET/CT spotted tumors in 117 men (10%) that mpMRI missed
  • The combined modalities identified index tumors with Gleason Scores of ≥3+4 in 92% of men (vs. 80% w/ only mpMRI & 82% w/ only PSMA PET/CT)
  • 68Ga-PSMA PET/CT and mpMRI performed similarly for lesion/tumor detection and localization

Better Assessments and Decisions – In addition to identifying more tumors, mpMRI and 68Ga-PSMA PET/CT’s combined localization accuracy might improve biopsy targeting, leading to more accurate tumor grading and better management decisions.

More Necessary Biopsies – Meanwhile, patients with negative mpMRI and 68Ga-PSMA PET/CT findings would likely have a low risk of clinically significant prostate cancer, making them solid candidates for active PSA monitoring and allowing them to avoid unnecessary biopsies.

The Takeaway – This approach needs a lot more research and PSMA tracers currently only have FDA approval for patients with metastatic prostate cancer or biochemical recurrence, so 68Ga-PSMA PET/CT won’t be combined with mpMRI in early diagnostic exams very soon. That said, this study suggests that we’ll see more future efforts to combine and evaluate mpMRI + 68Ga-PSMA PET/CT as an early diagnostic step.

Get every issue of The Imaging Wire, delivered right to your inbox.